Neuroprotective implant for treatment of glaucoma in phase II trial

June 10, 2019

Julianne Mobilian

Julianne Mobilian

Conferences | ASCRS

Here's the latest innovations at Neurotech Pharmaceuticals, Inc.

Rich Small, CPA, CEO of Neurotech Pharmaceuticals, Inc., shares what's in the pipeline for retina, glaucoma therapies.